The estimated Net Worth of Capital Lp Wexford Gp Llcda... is at least $143 Million dollars as of 16 June 2022. Capital Llcda owns over 45,382 units of Nephros Inc stock worth over $42,288,326 and over the last 11 years Capital sold NEPH stock worth over $100,453,142.
Capital has made over 8 trades of the Nephros Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital bought 45,382 units of NEPH stock worth $97,117 on 16 June 2022.
The largest trade Capital's ever made was selling 1,101,755 units of Nephros Inc stock on 2 March 2015 worth over $78,907,693. On average, Capital trades about 137,569 units every 233 days since 2013. As of 16 June 2022 Capital still owns at least 22,434,125 units of Nephros Inc stock.
You can see the complete history of Capital Llcda stock trades at the bottom of the page.
Over the last 5 years, insiders at Nephros Inc have traded over $0 worth of Nephros Inc stock and bought 188,822 units worth $443,998 . The most active insiders traders include Capital Lp Wexford Gp Llcda..., Robert R. Jr. Banks, and Andrew Astor. On average, Nephros Inc executives and independent directors trade stock every 70 days with the average trade being worth of $15,834. The most recent stock trade was executed by Arthur H Amron on 28 May 2024, trading 5,000 units of NEPH stock currently worth $11,200.
nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
Nephros Inc executives and other stock owners filed with the SEC include: